- Home
- About
- Team
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - indian pharma
- DISHMAN PHARMA - J.B.CHEMICALS
DISHMAN PHARMA vs J.B.CHEMICALS - Comparison Results
DISHMAN PHARMA 
Change
Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More
J.B.CHEMICALS
JB Chemicals and Pharmaceuticals Limited (JBCPL), the flagship of the Unique Group, is one of the India's leading transnational pharmaceutical company. The company has 11 manufacturing facilities at four locations in India (Belapur, Ankleshwar, Panol... More
Current Valuations
| DISHMAN PHARMA | J.B.CHEMICALS | DISHMAN PHARMA/ J.B.CHEMICALS |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 25.1 | 18.5 | 135.5% | View Chart |
| P/BV | x | 3.3 | 2.5 | 133.5% | View Chart |
| Dividend Yield | % | 0.7 | 0.2 | 429.8% |
Financials
 DISHMAN PHARMA  J.B.CHEMICALS |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| DISHMAN PHARMA Mar-16 |
J.B.CHEMICALS Mar-16 |
DISHMAN PHARMA/ J.B.CHEMICALS |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 374 | 318 | 117.7% | |
| Low | Rs | 129 | 200 | 64.6% | |
| Sales per share (Unadj.) | Rs | 197.8 | 148.0 | 133.7% | |
| Earnings per share (Unadj.) | Rs | 21.2 | 19.1 | 111.1% | |
| Cash flow per share (Unadj.) | Rs | 34.7 | 23.9 | 145.0% | |
| Dividends per share (Unadj.) | Rs | 2.00 | 0.50 | 400.0% | |
| Dividend yield (eoy) | % | 0.8 | 0.2 | 411.4% | |
| Book value per share (Unadj.) | Rs | 179.9 | 128.9 | 139.5% | |
| Shares outstanding (eoy) | m | 80.69 | 84.82 | 95.1% | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 1.3 | 1.7 | 72.7% | |
| Avg P/E ratio | x | 11.9 | 13.6 | 87.5% | |
| P/CF ratio (eoy) | x | 7.2 | 10.8 | 67.1% | |
| Price / Book Value ratio | x | 1.4 | 2.0 | 69.7% | |
| Dividend payout | % | 9.4 | 2.6 | 360.0% | |
| Avg Mkt Cap | Rs m | 20,306 | 21,951 | 92.5% | |
| No. of employees | `000 | 0.8 | 2.7 | 30.3% | |
| Total wages/salary | Rs m | 5,355 | 1,841 | 290.8% | |
| Avg. sales/employee | Rs Th | 19,252.7 | 4,590.9 | 419.4% | |
| Avg. wages/employee | Rs Th | 6,459.5 | 673.4 | 959.2% | |
| Avg. net profit/employee | Rs Th | 2,064.1 | 592.1 | 348.6% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 15,961 | 12,551 | 127.2% | |
| Other income | Rs m | 265 | 542 | 49.0% | |
| Total revenues | Rs m | 16,226 | 13,093 | 123.9% | |
| Gross profit | Rs m | 4,103 | 2,055 | 199.7% | |
| Depreciation | Rs m | 1,091 | 412 | 264.5% | |
| Interest | Rs m | 944 | 96 | 986.8% | |
| Profit before tax | Rs m | 2,334 | 2,088 | 111.8% | |
| Minority Interest | Rs m | 0 | 0 | 0.0% | |
| Prior Period Items | Rs m | 1 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 624 | 469 | 132.9% | |
| Profit after tax | Rs m | 1,711 | 1,619 | 105.7% | |
| Gross profit margin | % | 25.7 | 16.4 | 157.0% | |
| Effective tax rate | % | 26.7 | 22.5 | 119.0% | |
| Net profit margin | % | 10.7 | 12.9 | 83.1% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 11,018 | 7,778 | 141.7% | |
| Current liabilities | Rs m | 9,517 | 4,358 | 218.4% | |
| Net working cap to sales | % | 9.4 | 27.2 | 34.5% | |
| Current ratio | x | 1.2 | 1.8 | 64.9% | |
| Inventory Days | Days | 110 | 55 | 202.1% | |
| Debtors Days | Days | 35 | 80 | 43.5% | |
| Net fixed assets | Rs m | 16,304 | 5,713 | 285.4% | |
| Share capital | Rs m | 161 | 170 | 95.2% | |
| "Free" reserves | Rs m | 12,907 | 10,547 | 122.4% | |
| Net worth | Rs m | 14,516 | 10,937 | 132.7% | |
| Long term debt | Rs m | 4,189 | 0 | - | |
| Total assets | Rs m | 29,805 | 15,574 | 191.4% | |
| Interest coverage | x | 3.5 | 22.8 | 15.2% | |
| Debt to equity ratio | x | 0.3 | 0 | - | |
| Sales to assets ratio | x | 0.5 | 0.8 | 66.4% | |
| Return on assets | % | 8.9 | 11.0 | 80.9% | |
| Return on equity | % | 11.8 | 14.8 | 79.6% | |
| Return on capital | % | 17.5 | 20.0 | 87.8% | |
| Exports to sales | % | 24.8 | 48.7 | 50.9% | |
| Imports to sales | % | 3.7 | 7.1 | 52.8% | |
| Exports (fob) | Rs m | 3,956 | 6,115 | 64.7% | |
| Imports (cif) | Rs m | 596 | 889 | 67.1% | |
| Fx inflow | Rs m | 4,952 | 6,169 | 80.3% | |
| Fx outflow | Rs m | 697 | 1,285 | 54.2% | |
| Net fx | Rs m | 4,255 | 4,884 | 87.1% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 2,786 | 1,397 | 199.5% | |
| From Investments | Rs m | -1,529 | -320 | 477.3% | |
| From Financial Activity | Rs m | -941 | -1,196 | 78.7% | |
| Net Cashflow | Rs m | 316 | -102 | -309.3% | |
Share Holding
| Indian Promoters | % | 61.4 | 55.4 | 110.8% | |
| Foreign collaborators | % | 0.0 | 0.3 | - | |
| Indian inst/Mut Fund | % | 3.7 | 3.4 | 109.1% | |
| FIIs | % | 12.7 | 3.9 | 325.6% | |
| ADR/GDR | % | 0.0 | 0.0 | - | |
| Free float | % | 22.1 | 37.0 | 59.7% | |
| Shareholders | 46,261 | 30,437 | 152.0% | ||
| Pledged promoter(s) holding | % | 35.8 | 0.0 | - |
Compare DISHMAN PHARMA With: SANOFI INDIA TORRENT PHARMA PLETHICO PHARMA CIPLA ABBOTT INDIA
Compare DISHMAN PHARMA With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)
|
| |
Today's Market
Sensex Ends 146 Points Lower; IT and Power Stocks Drag(Closing)
Indian share markets witnessed selling pressure during closing hours and ended their trading session marginally lower.Sectoral indices ended on a mixed note with realty stocks.
Related Views on News
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)
Feb 9, 2018US business was hit by pricing pressure although there was growth sequentially led by new product launches.
Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)
Feb 9, 2018Price erosion in generic US drugs continues but seems to be bottoming out.
Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)
Feb 2, 2018Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
More Views on NewsMost Popular
The RCom Bankruptcy: 5 Lessons for Smallcap Investors(Profit Hunter)
Feb 7, 2019Managements of companies can create or ruin their fortunes. Why is management quality such an important factor in valuing businesses? Read on to find out...
The One Real Estate Stock to Buy Now(The 5 Minute Wrapup)
Feb 13, 2019The real estate sector is ready to make a comeback. This is the stock to consider buying.
How We Pick the Most Profitable Stocks from the Portfolios of Super Investors(The 5 Minute Wrapup)
Feb 8, 2019This is the trick to following super investors and not losing money.
Small Caps Under Seige: Could This Be A Once-in-a-Decade Wealth Creating Opportunity?(Profit Hunter)
Feb 14, 2019Don't let the dark clouds hovering over small caps scare you into hiding; it will rain gold as sentiments recover. Indeed, there is a blood bath. And if you are a first time investor, the correction is deep enough to scare you out of markets.
Don't Be Afraid of the Market; Buy Stocks Like This One(The 5 Minute Wrapup)
Feb 14, 2019During this tough period in the market, a contrarian approach holds huge potential upside for this Smart Money Secrets stock.
More|
| |
DISHMAN PHARMA SHARE PRICE
May 29, 2017 (Close)
TRACK DISHMAN PHARMA
- Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON DISHMAN PHARMA
DISHMAN PHARMA 8-QTR ANALYSIS
COMPARE DISHMAN PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.